Mosaic Biosciences: Biologics Brief Wed, 10 Jun 2026 04:08:35 -0400 https://www.buzzsprout.com/2621187 en-us © 2026 Mosaic Biosciences: Biologics Brief yes 74dbe908-f9f6-557e-9b86-33810e61d269 Mosaic Biosciences episodic false The science and strategy of making protein therapeutic medicines.

The Biologics Brief is a podcast about the science and strategy behind making protein therapeutic medicines. Hosted by the scientists at Mosaic Biosciences, a biologics discovery CRO, each episode unpacks the real decisions behind antibody discovery and biologics development, the same conversations we have with our partners every day.

From choosing the right discovery platform to evaluating a CRO, scoping a campaign, and navigating difficult targets, we get practical about what actually moves a program forward.

Whether you're building at an early-stage biotech, working in pharma, or just curious about how modern medicines get made, you'll come away with sharper questions to ask and frameworks worth keeping.

mosaicbio.com

]]> Buzzsprout (https://www.buzzsprout.com) Mosaic Biosciences https://storage.buzzsprout.com/0p689kcxiov4e7nre5p8ibg0s081?.jpg Mosaic Biosciences: Biologics Brief How to Choose a CRO for Antibody Discovery How to Choose a CRO for Antibody Discovery Your antibody program doesn’t fail because you picked the “wrong platform” as often as it fails because you picked the wrong partner. We get specific about how to choose a preclinical CRO for antibody discovery by starting with the one thing that should drive every decision: the target clinical profile. If the CRO can’t translate your clinical goals into a practical, testable preclinical plan, you’re not buying confidence, you’re buying activity.

We talk about why outsourcing is so common across biotech and pharma, from capital efficiency to speed, and why a disease-agnostic contract research organization can be an advantage when you need battle-tested execution. Then we dig into what “fully integrated” really means in biologics development: not just finding antibody sequences, but carrying knowledge into functional assays, pharmacology, stability, developability, and the steps that support IND-enabling work.

We also cover the biggest traps buyers fall into when comparing CRO quotes. A low price can hide missing deliverables, thin characterization, or a handoff that leaves you hunting for the next vendor. You’ll hear the exact questions we think you should ask before you sign: what you get at the end of the first round, what minimum product is delivered if the campaign underperforms, who runs your program, and whether the CRO can clearly explain the pros and cons of different antibody discovery approaches for your target. If you find this useful, subscribe, share it with a teammate, and leave a review with the one CRO question you wish you had asked sooner.

mosaicbio.com

]]> Your antibody program doesn’t fail because you picked the “wrong platform” as often as it fails because you picked the wrong partner. We get specific about how to choose a preclinical CRO for antibody discovery by starting with the one thing that should drive every decision: the target clinical profile. If the CRO can’t translate your clinical goals into a practical, testable preclinical plan, you’re not buying confidence, you’re buying activity.

We talk about why outsourcing is so common across biotech and pharma, from capital efficiency to speed, and why a disease-agnostic contract research organization can be an advantage when you need battle-tested execution. Then we dig into what “fully integrated” really means in biologics development: not just finding antibody sequences, but carrying knowledge into functional assays, pharmacology, stability, developability, and the steps that support IND-enabling work.

We also cover the biggest traps buyers fall into when comparing CRO quotes. A low price can hide missing deliverables, thin characterization, or a handoff that leaves you hunting for the next vendor. You’ll hear the exact questions we think you should ask before you sign: what you get at the end of the first round, what minimum product is delivered if the campaign underperforms, who runs your program, and whether the CRO can clearly explain the pros and cons of different antibody discovery approaches for your target. If you find this useful, subscribe, share it with a teammate, and leave a review with the one CRO question you wish you had asked sooner.

mosaicbio.com

]]> Mosaic Biosciences Buzzsprout-19253930 Thu, 28 May 2026 11:00:00 -0400 2360 Antibody Discovery, CRO, Eric Furfine 1 1 full false